What Neumentum does

Neumentum, Inc. is a privately held, clinical-stage specialty pharmaceutical company developing a portfolio of non-opioid analgesic products to address the opioid crisis in pain management. Founded in 2017 and headquartered in Morristown, New Jersey (with a corporate address in Summit, NJ), the company operates with a small team of 1–10 employees and is led by co-founders Scott Shively (CEO) and Joseph Pergolizzi, M.D. (Executive Chairman), supported by CSO Robert B. Raffa, Ph.D. (formerly of Johnson & Johnson) and CMO Ilona Steigerwald, M.D. (formerly of Grünenthal).

The company's pipeline centers on two lead assets: NTM-001, a novel alcohol-free formulation of ketorolac (an NSAID) in a pre-mixed IV bag designed for 24-hour continuous infusion to manage moderately severe acute postoperative pain — potentially the first NSAID approved for continuous infusion in the U.S., with patent protection through 2032; and NTM-006, a non-opioid, non-NSAID, non-gabapentinoid new chemical entity licensed from Johnson & Johnson in 2019, in development as a once-daily oral treatment for chronic neuropathic and nociplastic pain. Supporting pipeline candidates include NTM-002 (an IV patient-controlled analgesia candidate) and additional early-stage non-opioid programs.

Neumentum's business model is pre-commercial and primarily licensing-oriented. It generates limited revenue through upfront payments, milestone payments, and royalties from licensing partnerships — most notably the October 2020 agreement with Nuance Biotech granting exclusive China development and commercialization rights for NTM-001 ($3M upfront, up to $50M in milestones, plus low-double-digit royalties). The planned U.S. go-to-market is enterprise field sales targeting hospital procurement, pharmacy & therapeutics committees, and anesthesia/pain specialists for formulary adoption. The company has been funded through multiple equity rounds totaling approximately $34–36M, including a 2017 Series A and a 2023 exempt securities offering of up to $20M to support Phase 3 execution.

Name

Neumentum

Legal name

Neumentum, Inc.

Website

https://neumentum.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Neumentum is a clinical-stage pharmaceutical company developing a portfolio of novel non-opioid analgesic products, including an IV ketorolac formulation (NTM-001) and an oral analgesic NCE (NTM-006), targeting hospital-based acute and chronic pain markets to address the opioid crisis.

Ownership category

akta.pro rank

Product category

Non-opioid analgesics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Non-opioid analgesics
• Pain management pharmaceuticals
• Acute postoperative pain
• Chronic neuropathic pain
• Neurology specialty drugs

Headquarters

HQ city

Morristown

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Revenue: Licensing agreements for NTM-001 and NTM-006 generate upfront payments, milestone payments tied to development and regulatory achievements, and royalty payments on net sales.
2. Equity Financing: Exempt securities offerings to raise capital for development operations. $20 million offering with $16.56 million already sold per SEC Form D.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Neumentum develops and commercializes novel non-opioid pain pharmaceutical products. Its lead candidate NTM-001 is an alcohol-free, pre-mixed bag formulation of ketorolac designed for 24-hour continuous IV infusion for moderately severe postoperative acute pain. NTM-006 is a non-opioid, non-NSAID, non-gabapentinoid oral new chemical entity for chronic neuropathic and nociplastic pain. The company has four non-opioid candidates in development targeting hospitals and chronic pain patients.

Product overview

Neumentum is a specialty pharmaceutical company developing a portfolio of non-opioid analgesic products for pain management. The company's core pipeline includes NTM-001 (an IV alcohol-free ketorolac formulation in pre-mixed bag for 24-hour continuous infusion targeting acute postoperative pain), NTM-006 (an oral non-opioid, non-NSAID new chemical entity for chronic neuropathic and nociplastic pain), NTM-002 (IV patient-controlled analgesia candidate), and early-stage pipeline candidates. The company aims to address the opioid crisis by providing effective pain relief without the risks of abuse, misuse, diversion, or life-threatening respiratory depression associated with opioids.

Differentiator

Problem solved

Functional benefit

Products and services

• NTM-001 (ketorolac pre-mixed bag for continuous infusion) Investigational, alcohol-free, stable formulation of ketorolac (an NSAID) in a pre-mixed bag designed for 24-hour continuous IV infusion in postoperative settings. Developed for management of moderately severe acute pain requiring analgesia at the opioid level, with the goal of reducing or eliminating opioid use after surgery. Target customers are hospitals, surgical centers, and anesthesia/pain management specialists.
• NTM-006 (oral analgesic, formerly JNJ-10450232) Once-daily oral new chemical entity (NCE) that is non-opioid, non-NSAID, and non-gabapentinoid, with a novel mechanism of action. In development for chronic neuropathic and nociplastic pain, addressing patients with limited safe long-term oral options. Licensed-in from Johnson & Johnson Family of Companies.
• NTM-002 (IV patient-controlled analgesia candidate) Early-stage IV patient-controlled analgesia candidate with potential to deliver opioid-strength analgesia, intended to reduce the need for opioids in clinical acute pain settings.
• Early Stage Pipeline Early-stage non-opioid pharmaceutical pipeline candidates for the treatment of acute and chronic pain, both in the United States and globally, completing a portfolio of four novel non-opioid products.

Quantifiable outcome

• Steady plasma levels of ketorolac over 24 hours demonstrated in Phase I study with 67 subjects
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered secondary and core.

• NEMA Research Inc.secondaryStrategic or Co-development Partner · 20 September 2021Clinical research organization partnership, jointly nominated for Citeline Awards 2021 for Most Successful Early-Phase Research. NEMA Research provides clinical trial services for Neumentum's pain management product development.
• Nuance Biotech Co. LtdcoreOEM/ Whitelabel/ Licensing Partner · 21 October 2020Licensing agreement granting Nuance exclusive rights to develop and commercialize NTM-001 (ketorolac for IV infusion) in China. Neumentum receives $3 million upfront payment with potential development, regulatory and sales milestone payments up to $50 million plus low-double-digit percentage royalties on net sales. Nuance is a China-based specialty pharmaceutical company focused on pain management, founded in 2014.
• Janssen Pharmaceutica NVcoreOEM/ Whitelabel/ Licensing Partner · 10 October 2019Global licensing agreement for JNJ-10450232 (now NTM-006) and portfolio of backup compounds. JNJ-10450232 is a novel oral analgesic compound that is neither an opioid nor NSAID, with Phase 2A clinical studies completed. Licensed from Johnson & Johnson Family of Companies.
• McNeil Consumer Pharmaceuticals Co.coreOEM/ Whitelabel/ Licensing Partner · 10 October 2019Part of Johnson & Johnson Family of Companies, co-licensor of NTM-006 oral analgesic compound.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Heron Therapeutics: Specialty pharmaceutical company developing non-opioid and oncology-supportive care products, including post-operative pain therapies (HTX-011/Zynrelef). Directly comparable as a non-opioid pain-focused specialty pharma with hospital channel commercialization.
• Pacira BioSciences: Commercial-stage specialty pharma focused on non-opioid pain management with Exparel (bupivacaine liposome injectable suspension). The most established non-opioid post-surgical pain company, comparable for both product category and hospital formulary GTM motion.
• Trevena: Specialty pharma focused on non-opioid pain therapeutics, with FDA-approved OLINVYK (oliceridine), an IV opioid agonist for moderate-to-severe acute pain. Comparable as a small-cap non-opioid pain developer with similar hospital-channel commercialization.
• Cara Therapeutics: Clinical-stage biopharma developing novel peripherally-acting kappa opioid receptor agonists for chronic pruritus and pain. Comparable as a small specialty pharma targeting non-opioid pain pathways with similar development-stage profile.
• AcelRx Pharmaceuticals: Specialty pharma commercializing DSUVIA (sufentanil sublingual) and ZALVISO for acute pain in medically supervised settings. Comparable focus on opioid-sparing or alternative pain therapies with hospital/clinical channel strategy.
• Centrexion Therapeutics: Clinical-stage biopharma developing non-opioid treatments for chronic pain (e.g., CNTX-6016, capsaicin-based therapies). Directly comparable as a pure-play non-opioid pain therapeutics developer targeting similar patient populations.

Emerging players

• Baudax Bio: Specialty pharma with ANJESO (meloxicam IV) for moderate-to-severe pain and a non-opioid portfolio. Comparable as a small-cap non-opioid pain developer with hospital-channel commercialization focus.
• Concentric Analgesics: Clinical-stage biopharma developing CA-008, a non-opioid prodrug of capsaicin for post-surgical pain. Directly comparable as an emerging non-opioid acute pain developer with similar Phase-stage profile.

Broad incumbents

• Pfizer: Global pharmaceutical incumbent with established ketorolac generic franchise (Toradol) and broad pain portfolio. Comparable as a competitor and potential strategic acquirer/partner for non-opioid pain assets with deep hospital relationships.
• Grünenthal GmbH: Privately-held European specialty pharma with deep focus on pain management (including Qutenza, tapentadol/Palexia). Highly comparable as a chronic and acute pain specialist incumbent and potential strategic acquirer given Neumentum's CMO Ilona Steigerwald previously led late R&D there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neumentum-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neumentum